Targeting glutathione metabolism: Partner in crime in anticancer therapy

Enrico Desideri, Fabio Ciccarone, Maria Rosa Ciriolo

Research output: Contribution to journalReview articlepeer-review


Glutathione (GSH) is the predominant low-molecular-weight antioxidant with a ubiquitous distribution inside the cell. The steady-state level of cellular GSH is dependent on the balance between synthesis, hydrolysis, recycling of glutathione disulphide (GSSG) as well as cellular extrusion of reduced, oxidized, or conjugated-forms. The augmented oxidative stress typical of cancer cells is accompanied by an increase of glutathione levels that confers them growth advantage and resistance to a number of chemotherapeutic agents. Targeting glutathione metabolism has been widely investigated for cancer treatment although GSH depletion as single therapeutic strategy has resulted largely ineffective if compared with combinatorial approaches. In this review, we circumstantiate the role of glutathione in tumour development and progression focusing on how interfering with different steps of glutathione metabolism can be exploited for therapeutic purposes. A dedicated section on synthetic lethal interactions with GSH modulators will highlight the promising option of harnessing glutathione metabolism for patient-directed therapy in cancer.

Original languageEnglish
Article number1926
Issue number8
Publication statusPublished - Aug 2019


  • Cancer therapy
  • Ferroptosis
  • GSH
  • Synthetic lethality

ASJC Scopus subject areas

  • Food Science
  • Nutrition and Dietetics


Dive into the research topics of 'Targeting glutathione metabolism: Partner in crime in anticancer therapy'. Together they form a unique fingerprint.

Cite this